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intake on physiological effects and performance: A systematic review
Abstract
Introduction: This systematic review aims to examine the effects of the CYP1A2 −163C>A and ADORA2A
1976T>C polymorphism on physiological effects and performance relative to caffeine consumption.
Material and Methods: In this study, electronic databases including PubMed, Web of Science Core
Collection, Korean Journal Database, Russian Science Citation Index, SciELO Citation Index, Scopus,
ScienceDirect, ProQuest Dissertations & Thesis Global and EBSCO were searched. Results: The results
highlight that individuals with the TT or CT/CC genotype can have differences in caffeine consumption,
and C carriers may have increases in the maximum oxygen uptake (VO2max). The AA or AC/CC
genotypes can have different caffeine consumption and VO2max. In four studies, TT or CT/CC either in
AA or CC genotype had different physiological effects. Regardless of the amount of caffeine (3 mg/kg-5
mg/kg), Carriers of the C allele in the genotype ADORA2A gene have higher sports performance. Six
studies revealed a significant correlation between the AA genotype and performance following caffeine
intake. Conclusions: Genotype variations in ADORA2A and CYP1A2 may modulate the ergogenic effects
of caffeine, but some physiological effects can occur for different genotypes.
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Abstract: Introduction: This systematic review aims to examine the effects of the CYP1A2 −163C>A
and ADORA2A 1976T>C polymorphism on physiological effects and performance relative to caffeine
consumption. Material and Methods: In this study, electronic databases including PubMed, Web of
Science Core Collection, Korean Journal Database, Russian Science Citation Index, SciELO Citation
Index, Scopus, ScienceDirect, ProQuest Dissertations & Thesis Global and EBSCO were searched. Results: The results highlight that individuals with the TT or CT/CC genotype can have differences in
caffeine consumption, and C carriers may have increases in the maximum oxygen uptake (VO2max).
The AA or AC/CC genotypes can have different caffeine consumption and VO2max. In four studies,
TT or CT/CC either in AA or CC genotype had different physiological effects. Regardless of the amount
of caffeine (3 mg/kg-5 mg/kg), Carriers of the C allele in the genotype ADORA2A gene have higher
sports performance. Six studies revealed a significant correlation between the AA genotype and performance following caffeine intake. Conclusions: Genotype variations in ADORA2A and CYP1A2 may
modulate the ergogenic effects of caffeine, but some physiological effects can occur for different genotypes.
Keywords: CYP1A2, ADORA2A, ergogenic substance, polymorphism, genetics.
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1. Introduction
Caffeine is widely used as an ergogenic aid in sports due to enhancing physical performance among athletes [1]. Low-medium doses of caffeine (3–6 mg.kg) have a potential
to improve performance [2, 3]. Caffeine supplementation may be beneficial for muscle
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power, timing, psychomotor, endurance, effort, physiological effects, exercise and cognitive performance [4]. The response to caffeine cannot be uniform in individuals. Caffeine
supplementation can improve athletes’ performance, but others may not change, or performance may remain stable [5].
Inter individual variation in caffeine response may be due to polymorphisms in the
Cytochrome P450 Family 1 Subfamily A Member 2 (CYP1A2) gene (encoded enzyme responsible for up to 95% of caffeine metabolism) [A to C substitution at position 163C>A
(rs762551)] and the Adenosine A2A Receptor (ADORA2A) gene (may affect the responses
of acute caffeine ingestion) [T to C substitution at position 1976T>C (rs5751876)] [4, 6]. The
AA genotype is considered “fast metabolizers” and AC/CC genotypes are considered as
“slow metabolizers” of caffeine [6–8]. The TT genotype is considered as “high” and the
CC/CT genotypes are considered as “low” responders to caffeine [4]. There are studies
conducted with acute caffeine intake on the performance of athletes with CYP1A2 polymorphism distributions [2], but their results are contradictory. Guest et al. reported that
4mg/kg caffeine supplementation improved the performance of those with the AA genotype, but had no positive effect on those with the AC/CC genotype [9]. On the other hand,
apart from the CYP1A2 gene, there are studies on performance changes of caffeine supplements on ADORA2A gene distributions [7]. Loy et al. reported that caffeine supplementation improved cycling performance in TT athletes compared to C-Carriers [10].
However, after acute caffeine intake, C-allele carriers can have an ergogenic response, or
there are also studies with no effect [4, 11, 12]. Caffeine reduced the mean heart rate (HR)
irrespective of ADORA2A or CYP1A2 genotypes [13]. Thus, Womack et al. reported an
increase in the mean HR during the time trial compared with placebo and also found no
significance in the CYP1A2 genotype [14]. Ratings in the perceived exertion (RPE) did not
induce any changes with caffeine supplementation, and no significance was found with
genotype ADORA2A [10] or reduced RPE [15]. Studies with CYP1A2 and ADORA2A are
limited, and there are contradictions in studies. Recently, Grgic et al. conducted a systematic review of the ergogenic effects of acute caffeine supplements according to CYP1A2
gene polymorphism on sports performance [16]. However, ADORA2A gene polymorphism and physiological effects are also important in acute caffeine effects. We combined
the ADORA2A and CYP1A2 polymorphism results with physiological effect and sport
performance data from randomize controlled trails (RTCs) to identify ergogenic effects
which changed after acute caffeine intake and which harbored polymorphisms that
showed evidence of association.
The ergogenic effects of caffeine intake in athletes and the genetic background effect
on performance may be relevant [17]. The importance of this systematic review is to encourage more than multiple genetic polymorphisms of caffeine intake regarding different
ergogenic effects, not just performance. Therefore, our results have implications not only
for understanding individual differences in caffeine consumption and sport performance
but also for many physiological effects such as the heart rate (HR), blood pressure (SBP),
respiratory exchange ratio (RER), RPE, minute ventilation (VE), breathing frequency (BF),
blood lactate concentration. This study will support new trials in this area and provide a
prediction for determining appropriate genotype-specific values, such as the dose and
frequency of caffeine intake, but it may also lead to new research on the effects of genetic
variation between individuals on physiological effects altered by caffeine intake.
2. Materials and Methods
2.1. Literature search s
This review was performed while following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [18]. A comprehensive search of the
following databases. PubMed, Web of Science (Web of Science Core Collection, Korean Journal Database, Russian Science Citation Index, SciELO Citation Index), Scopus, ScienceDirect,
ProQuest Dissertations & Thesis Global, EBSCO was performed. In all of these databases,
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the following syntax was used: (CYP1A2 OR ADORA2A) AND (caffeine) AND (exercise OR
endurance OR ergogenic OR performance).
The search for studies concluded on 21 April 2021 and was performed independently
by two authors of the review to minimize bias in the study selection.
2.2. Inclusion and Exclusion Criteria
Predefined inclusion and exclusion criteria were as follows: (a) English written peerreviewed RTCs, dissertation or thesis on humans; (b) studies that specify the distinction between CYP1A2 (AA or C carriers) and ADORA2A (TT or C carriers) genotype differences in
daily caffeine consumption and maximum oxygen uptake (VO2max); (c) studies that explore
the influence of CYP1A2−163C>A polymorphism and ergogenic effects of acute caffeine supplement on performance parameters and physiological parameters compared to placebo;
(d) studies that explore the effect of acute caffeine intake on physiological effects and performance in ADORA2A1976T>C polymorphism. Studies that had irrelevant title and abstract, reviews, editorials, conference abstracts, books, book chapters, commentaries, letters,
errata, registration of trials, case reports, animal studies including in vivo and vitro, nonEnglish articles and articles that do not meet the inclusion criteria were excluded.
2.3. Study Selection
All titles and abstracts obtained by electronic scanning were downloaded to the Zotero
library. The duplicate results were removed through the Systematic Review AssistantDeduplication Module (SRA-DM) [19] and via the Zotero software [20].
The following data were extracted: (a) author(s) (b) sample size, ADORA2A and
CYP1A2 genotype distribution, and participants’ characteristics (sex, age, body mass, habitual caffeine intake, and training status); (c) exercise task(s) and caffeine supplementation
protocol; (d) main outcomes for example caffeine/genotype, VO2max/genotype and ergogenic effects of caffeine supplementations on performance/genotype interactions.
2.4. Calculation of Effect Sizes
Cohen's d effect sizes (ESs) were calculated by dividing the caffeine-placebo mean
change by the pooled standard deviation for each genotype separately. ESs can be interpreted as "large" (> 0.80), "medium" (0.51–0.80), "small" (0.21–0.50), "unimportant" (0.20).
2.5. Quality Appraisal
PEDro scale (11-point) was used to measure the quality of the studies included [21].
Item 1 in the scale was excluded from total score according to recommendations. Randomization, hidden allocation, blinding, attrition and data reporting were included in the validation of studies. The scored table was assessed with 1 or 0 for meeting or not meeting the
criteria respectively. 10 was the maximum score that could be assessed. Studies were classified as "poor" quality (3 points), "moderate" quality (4–5 points), "good" quality (6–8 points),
"excellent" methodological quality (9–10 points) [37]. Two authors performed assessment
independently, and final results were clarified by all authors.
3. Results
The initial study search resulted in 7,060 studies. After screening the titles and abstracts, removing duplicates from the original 3,998 studies, 348 articles were selected for
full-text reading (Figure 1). The selection process led to the inclusion of twenty-five randomized controlled trials [2, 3, 4, 9–14, 22–36, 38]. Seven were included for the ADORA2A
gene [4, 10, 11, 12, 13, 30, 34], and twenty-one were included for the CYP1A2 gene [2, 3, 4,
9, 12–14, 22–29, 31–33, 35, 36, 38]. In three studies, ADORA2A and CYP1A2 genes were
studied together [4, 12, 13]. In all of the aforementioned studies, we analyzed data regarding a total number of 954 healthy individuals. In particular, of these 671 subjects, 332 were
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AA genotype, 339 were C carriers of CYP1A2 gene and of these 283 subjects, 82 were TT
genotype, 201 were C carriers of ADORA2A gene.

Fig. 1. PRISMA Flow diagram [18].
Caffeine Intake and VO2max
ADORA2A: Four studies explored the effect of ADORA2A 1976T>C on caffeine consumption (Table 1). In two of these studies, the TT genotype was consuming more caffeine
than C carriers [4, 13] with ESs 0.16–0.32; in one study, C carriers consumed more caffeine
with the ES of 0.61 [10], and O’Connor et al. reported controversial results – the TT genotype consumed more caffeine than CC genotype but less than CT genotype with the ESs
0.14, 0.62 respectively [30]. Three studies examined the effect of ADORA2A 1976T>C on
VO2max; in all of them, C carriers were higher with ESs 0.44–0.68 [4, 10, 13].
CYP1A2: Nine studies reported the effect of CYP1A2 −163C>A on caffeine consumption (Table 2). In four of them, C carriers consumed more caffeine in daily life with ESs
0.0071–0.12 [4, 13, 14, 24]. In four others, AA genotypes consumed more dietary caffeine
with ESs 0.011–2.31 [9, 22, 27, 28]. On the other hand, the AC genotype consumed caffeine
more than AA genotypes (ESs 1.85), and the CC genotype more than AA genotype (ESs
0.36) [9]. Also, Spineli et al. reported contrary results – the AC genotype consumed more
caffeine than AA (ESs 0.38), and AA more than the CC genotype with ESs 0.50 [36].
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Six studies detected the effect of CYP1A2 −163C>A on VO2max. In four, the AA genotype had higher VO2max in C carriers in ESs 0.029–0.49 [4, 9, 13, 23]. Giersch et al. [27]
reported a higher degree of C carriers (ESs 0.12), and there was no difference in the study
by Pataky et al. [31].
Physiological Effects
ADORA2A: The study samples varied from 12–110 individuals; in some studies only
men were included, but mostly the sexes were mixed (the total number of participants:
281). Out of six, four studies reported significant results on genotype distribution for physiological effects [10, 12, 30, 34] while in all studies caffeine affected HR, RER, VE, BF, blood
lactate concentration, RPE with also contradictory results in HR, RPE, DBP, SBP [4,13]. HR
increased more in C carriers (ESs TT:0.3, C carriers: 0.5) [10]. Peak change SBP increased
in the TT genotype compared with C carriers [34]. Pain ratings (ESs TT: 0.033, CT: 0.36,
CC:0.092) decreased in the TT genotype and increased in the CC genotype, RPE (ESs
TT:0.12, CT:0.30, CC:0.057) and arm swelling decreased in the CC genotype, while caffeine
sensitivity increased after the exercise with 5 mg/kg caffeine [30]. Increased activeness and
urine production were seen in the TT genotype after ingesting 3 mg/kg CAF before the
exercise [12].
CYP1A2: In sixteen studies, physiological effects were measured after caffeine intake.
In seven studies, HR changed. Exercise HR increased in the AA genotype after ingesting
6 mg/kg caffeine [25, 28]. Guest et al. showed HR increases in AC genotypes after 4 mg/kg
caffeine intake, while a decrease was seen in CC genotype, and no differences were seen
in the AA genotype [9]. Meanwhile, a decrease in time for HR was detected in C carriers,
so the recovery time improved [38]. Apart from genotype distributions, HR values were
higher in the caffeine intervention group [4, 29, 35]. By contrast, it was low in another
study [13]. RPE was measured in twelve studies. In seven of them, no difference was seen
after acute caffeine consumption, and no effect was found in genotype distributions [2, 4,
14, 26, 32, 35, 36]. Two studies reported an increase in RPE in the placebo group [29, 32].
Guest et al. [9] found that 4mg/kg caffeine intake decreased RPE in AA genotype; moreover, Puente et al. suggested the same with 3 mg/kg of caffeine intake [33]. On the other
hand, Fitzgerald reported that C allele carriers had a decrease in RPE after 6 mg/kg of
caffeine intake [25], and also in 9-km Guest found no difference in genotype distributions;
in general tests, RPE did not change in C carriers [9]. In four studies, RER was measured.
Two studies supported that RER increased after 5 mg/kg of acute caffeine intake [13, 29].
Also being a C carrier can be more effective for RER increase after 5mg/kg of caffeine
intake [13]. Fitzgerald detected RER decrease in C carriers after 6mg/kg of caffeine intake
[25], while no effect in RER was found in study by Womack et al. [14]. When respiratory
parameters were evaluated, Glaister et al. found minute ventilation and breathing frequency increased in the caffeine group. In addition, blood lactate levels increased, which
is also supported in the study by Potgieter [13, 32]. In this study after 6 mg/kg, shakiness,
heart palpitations and gastrointestinal system (GIS) disturbances were seen [32]. In general, insomnia was seen in C carriers after consuming 3 mg/kg [12], and also insomnia in
AA genotypes was detected [33]. Puente et al. and Salinero et al. reported no side effects
and stable fatigue index after 3 mg/kg caffeine intake, but nervousness was detected by
Salinero et al. in C carriers [2, 33]. In four studies, the range of ESs in the AA genotype on
HR is 0.080–0.86 and in C carriers 0.13–9.52. In six studies, the range of ESs for RPE is 0.0–
0.45 in the AA genotype, and in six studies 0.0–1.34 in C carriers. In two studies, the range
of in AC genotype was 0.12–0.37 and in an one study the Ess value was 0.16 in CC genotype [14] (see Table 2).
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Table 1. Characteristics and outcomes of included studies in the ADORA2A gene.
Author
(year,
location)

Study
Design

Carswell et
al. (2020),
U.K. [4]

RCT

Glaister et
al. (2020),
U.K. [13]

RCT

Study
Sample

Age
year)

VO2max

Healthy
active
adults
(N=18)

24 ± 4

TT (n=11):
46.8 ± 10.4
C allele
carriers (n=7):
48.4 ± 6.8
*ml/kg/min

Cyclist
(N=66)

41.9 ±
8.6

TT (n=16):
4.05 ± 0.45
CT (n=14):
4.07 ± 0.46
CC (n=10):
4.33 ± 0.37
*l/min

Intervention
of the
experimental
group
3 mg/kg BW
CAF

5 mg/kg BW
CAF

Intervention of
the control
group

Genotype
distribution

Caffeine
intake
(mg/day)

Outcomes

Effect Size

3 mg/kg BW
(microcrystalline)

TT (n=11), C
allele carriers
(n=7)

TT (n=11): 143
± 139
C allele
carriers (n=7):
104 ± 126

TT/C genotype:
VO2max mL/kg/min 0.18

TT (n=24), C
allele carriers
(n=42)

TT (n=16): 359
± 108
CT (n=14):
337 ± 158
CC (n=10):
326 ± 100

↑Performance (CAF intervention)
*p<0.001
→Performance (CAF intervention x
genotype distribution) *p>0.05
↑Total work (CAF intervention)
*p<0.001
→Total work (genotype
distribution) *p<0.001
↑Mean HR (CAF intervention
during the TT) *p<0.01
→Mean HR (CAF intervention at
%70 VO2max) *p>0.05
→Mean HR (genotype distribution)
*p>0.05
→RPE (genotype distribution or
CAF intervention) *p>0.05
↑Cognitive performance with
reaction time (CAF intervention)
*p<0.01
↑PVT (CAF intervention) *p<0.01
REST;
↑DBP, SBP (CAF intervention)
*p<0.05
→DBP (Genotype distribution)
*p=0.15
→SBP (Genotype distribution)
*p=0.21
→BF, BGI, BLa, VO2, (CAF
intervention)
↓HR (CAF intervention) *p<0.05
↑RER, V� E (CAF intervention)
*p<0.05
→BF *p=0.305, BGI *p=0.494, BLa
*p=0.874, HR *p=0.969, RER
*p=0.140, V� E *p=0.335, VO2
*p=0.903 (intervention x genotype
distribution)

Placebo
(maltodextrin)

TT/C genotype:
CAFF intake 0.29

TT/TC genotype
VO2max (L/min) 0.044
CAFF intake 0.16
TT/CC genotype
VO2max (L/min) 0,68
CAFF intake 0.32
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Author
(year,
location)

Grgic et al.
(2020),
Australia
[11]

Study
Design

RCT

Study
Sample

Resistancetrained men
(N=20)

Age
year)

29.3 ±
4.8

VO2max

NA

Intervention
of the
experimental
group

3 mg/kg BW
CAF

Intervention of
the control
group

Placebo
(dextrose)

Genotype
distribution

C allele
carriers
(n=20)

Caffeine
intake
(mg/day)

C allele
carriers
(n=20): 143 ±
113

Outcomes

INCREMENTAL EXERCISE;
HR, BF, BGI, BLa, RER, V� E, VO2 (CAF
intervention x exercise intensity)
*p<0.001
↓HR (CAF intervention) *p <0.001
↑BLa (CAF intervention) *p<0.001
↓RPE (CAF intervention) *p<0.001
↑V� E (CAF intervention) *p=0.008
↑RER (CAF intervention) *p=0.016
→HR, BF, BGI, BLa, RER, V� E, VO2,
RPE (CAF intervention or genotype
distribution)
TIME-TRIAL;
↑BF, BGI, BLa, mean HR, RER,
mean V� E (CAF intervention)
*p<0.05
↑Mean power output (CAF
intervention) *p<0.001
↓TT completion time (CAF
intervention) *p<0.001
→TT completion time (Genotype
distribution)*p=0.752
→ VO2 (CAF intervention)
*p=0.172
↑BF, BGI, BLa, HR, RER, V� E, (CAF
intervention) *p<0.05
CAF INTERVENTION VS. PLACEBO
IN C ALLELE CARRIERS;
↑Maximum repetitions at 85%
1RM *p<0.001
↑Mean power matched for
repetitions (W) *p<0.001
↑Mean velocity matched for
repetitions (m/s) *p<0.001
↑Peak power matched for
repetitions (W) *p<0.001
↑Peak velocity matched for
repetitions (m/s) *p<0.001

Effect Size

MUSCLE ENDURANCE
TEST;
Maximum repetitions at
85% 1RM
C allele carriers 0.58
Mean power matched for
repetitions (W)
C allele carriers 0.56
Mean velocity matched
for repetitions (m/s)
C allele carriers 0.96
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Author
(year,
location)

Loy et al.
(2015), U.S.
[10]

Study
Design

RCT

Study
Sample

Tennis
players
(N=12)

Age
year)

NA

VO2max

TT (n=6):
31.62 ± 4.35
C allele
carriers (n=6):
33.78 ± 8.35
*ml/kg/min

Intervention
of the
experimental
group

5 mg/kg BW
CAF

Intervention of
the control
group

Placebo (flour)

Genotype
distribution

TT (n=6), C
allele carriers
(n=6)

Caffeine
intake
(mg/day)

TT (n=6):
53.23 ± 76.57
C allele
carriers (n=6):
102.02 ±
83.78

Outcomes

Effect Size

↑Vertical jump height (cm)
*p=0.034
↑Peak power in the Wingate test
(W) *p<0.001
↑Mean power in the Wingate test
(W) *p<0.001
↑Minimum power in the Wingate
test (W) *p=0.020

Peak power matched for
repetitions (W)
C allele carriers 0.27
Peak velocity matched for
repetitions (m/s)
C allele carriers 0.64
CMJ
C allele carriers 0.13
WINGATE TEST (W)
Peak power
C allele carriers 0.37
Mean power
C allele carriers 0.34
Minimum power
C allele carriers 0.41
TT/C genotype
CAFF intake 0.61
VO2max mL/kg/min 0.32

MODERATE EXERCISE;
↑%VO2peak (C allele carriers)
*p=0.01
→%VO2 (CAF intervention vs PLA
intervention) *p=0.60
→Mean VO2, HR, R, overall RPE,
leg muscle pain intensity (group x
condition) *p>0.43
PEAK EXERCISE;
→VO2peak, Wpeak, HRpeak,
RERpeak, overall RPEpeak, leg
muscle pain peak (genotype
distribution) *p>0.30
TIME TRIAL PERFORMANCE;
↑Total work (CAF intervention x
genotype distribution) *p=0.03
→Mean VO2, HR, overall RPE or leg
muscle pain (group x condition)
*p>0.28
↓%VO2 (TT group)

MODERATE EXERCISE;
VO2 mean (mL/kg/min)
TT genotype 0.2–C
carriers 0.009
% VO2 peak mean
(mL/kg/min)
TT genotype 0.4–C
carriers 0.06
Heart rate mean (bpm)
TT genotyoe 0.3–C
carriers 0.5
RPE mean (6–20)
TT genotyoe 0.8–C
carriers 0.5
Painmean (0–10)
TT genotyoe 0.6–C
carriers 0.16
TIME TRIAL
PERFORMANCE
Total work (kJ)
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Author
(year,
location)

Munoz et
al. (2020),
Spain [12]

Study
Design

RCT

Study
Sample

Handball
players
(N=31)

Age
year)

23.7 ±
2.8

VO2max

NA

Intervention
of the
experimental
group

3 mg/kg BW
CAF

Intervention of
the control
group

Placebo
(cellulose)

Genotype
distribution

TT (n=6), C
allele carriers
(n=25)

Caffeine
intake
(mg/day)

NA

Outcomes

↑Urine production (in TT genotype
higher than C allele carriers)
*p<0.001
↑Increased activeness (in TT
genotype higher than C allele
carriers) *p=0.016
→Insomnia *p=0.174, GI problems
*p=0.218, headache *p=0.108,
irritability *p=0.558, muscular pain
*p=0.094, tachycardia *p=0.282
(genotype distribution)
→CMJ *p=0.602, SV *p=0.866,
MATT *p=0.600, IHS *p=0.575,
BT7M *0.879, BT7M+GK *p=0.151,
BT9M *p=0.255, BT9M+GK
*p=0.443
ACC *p=0.409, DEC *p=0.810, BI
*p=0.753

Effect Size

TT genotype 0.27–C
carriers 0.03
VO2mean (mL/kg/min)
TT genotype 0.04–C
carriers 0.001
% VO2peak mean
(mL/kg/min)
TT genotyoe 0.07–C
carriers 0.11
Heart rate mean (bpm)
TT genotyoe 0.2–C
carriers 0.35
RPEmean (6–20)
TT genotyoe 0.82–C
carriers 0.71
Painmean (0–10)
TT genotyoe 0.55–C
carriers 0.28
CMJ (cm)
TT genotype 0.08 –C
carriers 0.018
SV (s)
TT genotype 0.16 –C
carriers 0.34
MATT (s)
TT genotype 0.016 –C
carriers 0.044
IHS (kg)
TT genotype 0.27 –C
carriers 0.036
BT7M (km/h)
TT genotype 0.12 –C
carriers 0.14
BT7M + GK (km/h)
TT genotype 0.12 –C
carriers 0.14
BT9M (km/h)
TT genotype 0.045 –C
carriers 0.34
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Author
(year,
location)

O’Connor et
al. (2018),
U.S [30]

Renda et al.
(2012), Italy
[34]

Study
Design

RCT

RCT

Study
Sample

Age
year)

Healthy
individuals
(N=26)

Healthy
men
(N=110)

VO2max

NA

26.6 ±
4

NA

Intervention
of the
experimental
group

5 mg/kg BW
CAF

3 mg/kg CAF

Intervention of
the control
group

Placebo (flour)

Placebo (decaf
preparation)

Genotype
distribution

TT (n=7), C
allele carriers
(n=19)

TT (n=28), C
allele carriers
(n=82)

Caffeine
intake
(mg/day)

Outcomes

TT (n=7): 46 ±
68
CT (n=12): 93
± 84
CC (n=7): 37 ±
56

↑Pain ratings (CC group) *p=0.056
↓Pain ratings (TT group) *p=0.172
↓Perceived exertion (CC group)
*p>0.05
↑Caffeine sensitivity (CC group)
*p>0.05
↓Caffeine consumption (CC group)
*p>0.05
↓Arm swelling (CC group vs CT/TT
groups) *p>0.05

NA

Mean SBP, DBP (CAF intervention)
*p<0.001
↑Peak SBP (CAF intervention)
*p<0.001
Peak DBP (CAF intervention) *p=NS
↑peak ΔSBP (TT group) *p=0.024
SBP (intervention x time
interaction) *p<0.01

Effect Size

BT9M + GK (km/h)
TT genotype 0.75 –C
carriers 0.23
ACC (number/min)
TT genotype 0.68 –C
carriers 0.071
DEC (number/min)
TT genotype 0.0038 –C
carriers 0.34
BI (number/min)
TT genotype 0.37 –C
carriers 0.14
TT/CT Genotype: CAFF
intake 0.62
TT/CC Genotype: CAFF
intake 0.14
Perceived exertion (6–
20): TT genotype 0.12, CT
genotype 0.30, CC
genotype 0.057
Pain (0–100): TT
genotype 0.033, CT
genotype 0.36, CC
genotype 0.092
Data not presented

Abbreviations: ACC: acceleration; BGI = blood glucose concentration; BF: breathing frequency; BI: body impacts; BLa: blood lactate concentration; BT7M: ball throw 7-m; BT7M+GK:ball throw 7-m with goalkeeper; BT9M: ball throw
9-m; BT9M+GK:ball throw 9-m with goalkeeper; BW: body weight; CAF: caffeine; CHO: carbohydrate; CMJ: countermovement jump; DBP: diastolic blood pressure; DEC: decelerations; GI: gastrointestinal; IHS: isometric handgrip
strength; HR: heart rate; MATT: modified agility t-test; NA: Not applicable; NS: No significant; PLA: placebo; PVT: psychomotor vigilance test; RER: respiratory exchange ratio; RPE: rating of perceived exertion; SBP: systolic blood
pressure; SV: sprint velocity test; TT: time-trial; VO2: rate of oxygen uptake; V̇E: minute ventilation; vs: versus; W: Watt.
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Table 2. Characteristics and outcomes of included studies in the CYP1A2 gene.
Author
(year,
location)
Algrain et
al. (2019),
U.S. [23]

Carswell et
al. (2020),
U.K. [4]

Study
Design

Study Sample

Age
(year)

VO2max

RCT

Young male
(N=19)

25 ± 4

AA (n=10):
31.9 ± 5.69
C allele
carriers (n=9):
31.7 ± 8.1
*ml/kg/min

3 gum x
100mg/piece
CAF

AA (n=10):
48.5 ± 6.3
C allele
carriers (n=8):
46.2 ± 11.9
*ml/kg/min

3 mg/kg BW
CAF

RCT

Healthy active
adults (N=18)

24 ± 4

Intervention

Control
Placebo (gum)

3 mg/kg BW
(microcrystalline)

Genotype
Distribution
AA (n=10), C
allele carriers
(n=9)

AA (n=10), C
allele carriers
(n=8)

Caffeine
Intake
(mg/day)
NA

AA (n=10):
121 ± 128
C allele
carriers (n=8):
135 ± 145

Outcomes

Effect Size

→Performance (CAF intervention)
*p=0.258
→Ergogenic effect (CAF
intervention x genotype
distribution) *p≥0.861
→Absolute work (CAF
intervention) *p=0.311
→Relative work (CAF
intervention) *p=0.258
→Genotype distribution x CAF
intervention interaction*p=0.861

AA/C genotype:
VO2max mL/kg/min
0.029

↑Performance (CAF intervention)
*p<0.001
→Performance (CAF intervention
x genotype distribution) *p>0.05
↑Total work (CAF intervention) *
p<0.001
→Total work (genotype
distribution) * p>0,05
↑Mean HR (CAF intervention
during the TT) *p <0.01
→Mean HR (CAF intervention at
%70 VO2max) *p>0.05
→Mean HR (genotype
distribution) *p>0.05
→RPE (genotype distribution or
CAF intervention) *p>0.05
↑Cognitive performance with
reaction time (CAF intervention)
*p<0.01
↓Reaction time (in AA group vs C
allele carriers) *p <0.01
↑PVT (CAF intervention) *p<0.01
↑Slowest %10 speed response
during exercise (in AA group vs C
allele carriers) *p<0.01

AA/C genotype:
VO2max mL/kg/min 0.24
AA/C genotype:
CAFF intake 0.10

Work (kJ)
AA genotype 0.049
C carriers 0.15
Relative work(kJ/kg)
AA genotype 0.24
C carriers 0.0
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Author
(year,
location)

Study
Design

Study Sample

Age
(year)

VO2max

Intervention

Control

Genotype
Distribution

Caffeine
Intake
(mg/day)

Colquhoun
(2019), U.S.
[24]

RCT

Healthy males
(N=42)

NA

NA

6 mg/kg BW
CAF

Placebo (flour)

AA (n=26) C
allele carriers
(n=16)

AA (n=26):
290.6 ± 295.1
C allele
carriers
(n=16): 324.7
± 276.3

Figueiredo
et al.
(2021),
Brazil [26]

RCT

Well trained
individuals
(N=10)

30.1 ±
6.4

NA

300 mg CAF

Placebo
(microcrystalline
cellulose)

CC (n=9),
AC (n=1)

NA

Fitzgerald
(2014), U.S.
[25]

RCT

Healthy men
(N=12)

24±1

NA

6 mg/kg BW
CAF

Placebo
(flovured water)

AA (n=6) C
(n=6)

NA

Outcomes
↓Fastest %10 reaction time at
rest post supplementation (in AA
group vs C allele carriers) *p<0.05
↓Number of lapses (in AA group
vs C allele carriers) *p<0.01
↑VLEI (C allele carriers) *p=0.032
↑MVIC (PLA intervention)
*p=<0.001
→MVIC (CAF intervention)
*p=0.094
↓MVT (PLA intervention)
*p=<0.001
Caffeine intake (AA genotype vs C
allele carriers) *p=0.715
→TT performance (CAF
intervention vs PLA intervention)
*p=0.89
→RPE (CAF intervention vs PLA
intervention) *p=0.34
→Vertical jump relative power
(intervention or time or time x
group) *p=0.67, p=0.4, p=0.66
Vertical jump relative power (CAF
intervention vs PLA intervention)
*p=0.34
→Resting HR (CAF intervention)
resting DBP in trials *p>0.05
↑Resting SBP (CAF intervention)
*p<0.05
↓RPE in 300 WATT (CAF
intervention) *p<0.10
↓RPE in 300 WATT (CAF
intervention) *p<0.10
RPE (time x genotype x
intervention)
RPE in trials (time x intervention)
*p<0.05
↓RPE (CAF intervention in C allele
carriers) *p<0.05

Effect Size

AA/C genotype:
CAFF intake 0.12

Data not presented.

Heart rate
AA/C genotype 0.96
RPE (6–20 score)
AA genotype 0.10
C carriers 1.34
RER
C carriers 0.6
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Author
(year,
location)

Study
Design

Study Sample

Age
(year)

VO2max

Intervention

Control

Genotype
Distribution

Caffeine
Intake
(mg/day)

Giersch et
al. (2018),
Canada [27]

RCT

Male
(N=20)

NA

AA (n=8):
56.6±9.6
C allele
carriers
(n=12):
57.7±9.5
*ml/kg/min

6 mg/kg BW
CAF

Placebo (flour)

AA (n=8), C
allele carriers
(n=12)

AA (n=8):
93.0 ± 111.2
C allele
carriers
(n=12): 91.6 ±
136.8

Glaister et
al. (2020),
U.K. [13]

RCT

Cyclist
(N=66)

41.9 ±
8.6

AA (n=22):
4.20 ± 0.43
C allele
carriers
(n=18): 4.03 ±
0.44
*l/min

5 mg/kg BW
CAF

Placebo
(maltodextrin)

AA (n=41), C
allele carriers
(n=25)

AA (n=22):
340 ± 136
C allele
carriers
(n=18): 346 ±
110

Outcomes
↑HR at peak exercise (AA
genotype than C carriers) *p<0.05
→HR at peak exercise and peak
power output
→VO2max (genotype x condition
x intervention)
→RER (CAF intervention)
↓RER (CAF intervention in C allele
carriers)
↑Average power output p=0,054
→Performance time (Genotype
distribution) *p=0.42
→Power output (Genotype
distribution) *p=0.98
TT performance (CAF
intervention) *p=0.03

REST.
↑DBP, SBP (CAF intervention)
p*<0.05
→DBP (Genotype distribution) *p
= 0.78
→SBP (Genotype distribution) *p
= 0.68
→BF, BGI, BLa, VO2, (CAF
intervention)
↓HR (CAF intervention) *p<0.05
↑RER, V� E (CAF intervention)
*p<0.05
→ BF *p=0.914, BGI *p=0.339, BLa
*p=0.127, HR *p=0.401, RER
*p=0.410, V� E *p=0.153, VO2 *p=
0.076 (genotype distribution)
INCREMENTAL EXERCISE.

Effect Size

AA/C genotype:
VO2max mL/kg/min 0.12
AA/C genotype:
CAFF intake 0.011
Serum Caffeine
AA/C genotype 1.4
Performance Time
AA 0.36
C carriers 0.24
Power Output
AA 0.23
C carriers 0.23
AA/C genotype:
CAFF intake 0.049
VO2max (l/min) 0.39
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Author
(year,
location)

Grgic et al.
(2020),
Australia
[22]

Study
Design

RCT

Study Sample

Resistancetrained men
(N=22)

Age
(year)

NA

VO2max

NA

Intervention

3 mg/kg CAF

Control

Placebo
(dextrose)

Genotype
Distribution

AA (n=13), C
allele carriers
(n=9)

Caffeine
Intake
(mg/day)

AA (n=13):
133 ± 123
C allele
carriers (n=9):
117 ± 68

Outcomes
HR, BF, BGI, BLa, RER, V� E, VO2
(CAF intervention x exercise
intensity) *p<0.001
→BF, BGI, VO2 (CAF intervention
or genotype distribution)
↓HR (CAF intervention) *p <0.001
↑BLa (CAF intervention) *p<0.001
↓RPE (CAF intervention)
*p<0.001
↑V� E (CAF intervention) *p=0.008
→BLa, RPE, V� E, (genotype
distribution)
↑RER (CAF intervention)
*p=0.016
→HR, BF, BGI, BLa, V� E, VO2, RPE
(CAF intervention or genotype
distribution)
RER (C allele carriers) *p=0.004
RER (AA group) *p=0.628
TIME-TRIAL.
↑BF, BGI, BLa, mean HR, RER,
mean V� E (CAF intervention)
*p<0.05
↑Mean power output (CAF
intervention) *p<0.001
↓TT completion time (CAF
intervention) *p<0.001
→TT completion time (Genotype
distribution) *p=0.286
→ VO2 (CAF intervention)
*p=0.172
↑BF, BGI, BLa, HR, RER, V� E, (CAF
intervention) *p<0.05
↑Movement velocity, power
output (CAF intervention) *p<0.05
↑Vertical jump height (CAF
intervention) *p=0.017
↑Power output in Wingate test
(CAF intervention) *p<0.05

Effect Size

AA/C genotype:
CAFF intake 0.16
Movement velocity and
power in the bench press
AA genotype 0.22–0.9
AC/CC genotype 0.14–
0.68
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Author
(year,
location)

Study
Design

Study Sample

Age
(year)

VO2max

Intervention

Control

Genotype
Distribution

Caffeine
Intake
(mg/day)

Outcomes
→Mean power, mean velocity,
peak power, peak velocity at 25,
50, 75, and 90% 1RM (genotype
distribution or CAF intervention x
genotype interaction) *p>0.05
↑Mean power, mean velocity,
peak velocity at 50% 1RM (CAF
intervention) *p<0.05
→Maximum number of
repetitions in the bench press
exercise with 85% 1RM (genotype
distribution or CAF intervention x
genotype interaction) *p=0.454
↑Maximum number of
repetitions in the bench press
exercise with 85% 1RM (CAF
intervention) *p<0.001
↑Mean velocity (C allele carriers)
*p<0.001
Mean velocity (Genotype
distribution) *p=0.034
→Mean velocity (CAF intervention
x genotype) *p=0.094, Genotype x
Caffeine interaction *p=0.094
→Peak velocity, mean power
output, and peak power output
(Genotype distribution or CAF
intervention x genotype
interaction) p>0.05
↑Peak velocity, mean power
output, and peak power output
(CAF intervention) *p<0.001
→CMJ (Genotype distribution)
*p=0.447
→CMJ (Genotype distribution x
CAF intervention) *p=0.752
↑CMJ (CAF intervention)
*p=0.017
→Peak power in Wingate
(Genotype distribution) *p=0.998

Effect Size
Muscle endurance and
velocity
AA genotype 0.62–1.25
AC/CC genotype 0.33–
1.27
CMJ
AA genotype 0.13
AC/CC genotype 0.19
Power output in the
Wingate
AA genotype 0.34–0.43
AC/CC genotype 0.32–
0.57
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Author
(year,
location)

Guest et al.
(2019),
Canada [9]

Study
Design

RCT

Study Sample

Competitive
male (N=101)

Age
(year)

25 ± 4

VO2max

AA (n=49):
3.9 ± 0.8
AC (n=44): 3.8
± 0.7
CC (n=8): 3.9
± 0.6
*l/min
AA (n=49): 49
±8
AC (n=44): 47
± 12
CC (n=8): 44 ±
12
*ml/kg/min

Intervention

2 and 4 mg/kg
CAF

Control

Placebo
(dextrose)

Genotype
Distribution

AA (n=49), C
allele carriers
(n=52)

Caffeine
Intake
(mg/day)

AA (n=49): 87
± 18
AC (n=44): 80
± 20
CC (n=8): 38 ±
24
*dietary
AA (n=49): 61
± 13
AC (n=44): 89
± 17
CC (n=8): 80 ±
74
*sport

Outcomes
→Peak power in Wingate
(Genotype x CAF interaction)
*p=0.542
↑Peak power in Wingate (CAF
intervention) *p< 0.001
→Mean power (Genotype
distribution) *p=0.517
→Mean power (CAF intervention
x genotype interaction) *p=0.583
↑Mean power (CAF intervention)
*p<0.001
→Minimum power (CAF
intervention x genotype
interaction) *p=0.396
→Minimum power (Genotype
distribution) *p=0.505
↑Minimum power (CAF
intervention) *p=0.011
↑Vigor/activeness, perception of
improved performance (C allele
carriers)
↓Cycling time (2–4 mg/kg BW
CAF intervention vs PLA
intervention) *p=0.04
↓10-km time (4 mg/kg BW CAF
intervention vs PLA intervention)
*p=0.01
↓Cycling time (4 mg/kg BW CAF
intervention in AA group vs PLA)
*p<0.0001
↓Cycling time (2 mg/kg BW CAF
intervention in AA group vs PLA)
*p=0.0005
→Cycling performance (2–4
mg/kg BW CAF intervention in AC
group) *p=0.43
↑Cycling time (4 mg/kg BW CAF
to CC group) *p=0.04

Effect Size

AA/CA genotype:
VO2max mL/kg/min 0.20
VO2ma l/min 0.13
CAFF intake dietary 0.37
CAFF intake sport 1.85
AA/CC genotype:
CAFF intake dietary 2.31
CAFF intake sport 0.36
VO2max mL/kg/min 0.49
VO2ma l/min 0.0
Cycling time
2 mg/kg CAF AA 2.26
4 mg/kg CAF AA 3.39
4 mg/kg CAF CC 3.75
Improvement
4 mg/kg AA 0.63
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Author
(year,
location)

Study
Design

Study Sample

Age
(year)

VO2max

Intervention

Control

Genotype
Distribution

Caffeine
Intake
(mg/day)

Klein et al.
(2012), U.S.
[28]

RCT

Tennis
players
(N=16)

20.7 ±
1.7

NA

6 mg/kg CAF

Placebo (shots)

AA (n=7), C
allele carriers
(n=9)

AA (n=7):
104.21 ±
33.78
C allele
carriers (n=9):
91.94 – 64.23

McGrath
(2015), New
Zealand
[29]

RCT

Healthy well
trained male
cyclists and
triathletes
(N=11)

31 ± 3

NA

5 mg/kg BW
CAF

Placebo (flour)

AA (n=6), C
allele carriers
(n=5)

NA

Outcomes
Greatest change in 10-km time (4
mg/kg BW CAF to CC group vs AA
and AC) *p=<0.0001, *p=0.0015
↓5-km RPE (4 mg/kg BW CAF
intervention in AA genotype)
*p=0.03
↑HR (4 mg/kg BW CAF
intervention in AC genotype vs
2mg/kg BW CAF and PLA
intervention) *p=0.007, *p=0.005
↓HR (4 mg/kg BW CAF
intervention in CC genotype vs
2mg/kg BW CAF and PLA
intervention) *p=0.05, *p=0.03
→9-km RPE (genotype
distribution)
→Total RPE (CAF intervention in C
allele carriers)
→HR (CAF intervention in AA
genotype)
↑Total success shots in TST (CAF
intervention) *p=0.029
↑HR in TM test (AA genotype)
*p=0.052

↑Self-paced cycling performance
*p=0.037
→Performance in TT (caffeine ×
genotype) *p=0.343
→RPE (caffeine x genotype
interaction) *p=0.484
No caffeine x ergogenic effect x
trial interaction *p=0.147

Effect Size
2 mg/kg AA 0.4
4 mg/kg CC 1.3

AA/C Genotype
CAFF intake 0.24
RPE
AA genotype 0.11 (TM) –
0.20 (TST)
C carriers 0.23(TST)–
0.38(TM)
HR
AA genotype 0.11(TST)–
0.37 (TM)
C carriers 0.13(TST)–0.17
(TM)
Data not presented
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Author
(year,
location)

Munoz et
al. (2020),
Spanish
[12]

Study
Design

RCT

Study Sample

Handball
players
(N=31)

Age
(year)

23.7 ±
2.8

VO2max

NA

Intervention

3 mg/kg CAF

Control

Placebo
(cellulose)

Genotype
Distribution

AA (n=14),
AC (n=15), CC
(n=2)

Caffeine
Intake
(mg/day)

NA

Outcomes
↑ HR during the TT (CAF
intervention) *p=0.003
→HR (CAF intervention x
genotype interaction) *p=0.118
↑During steady state exercise HR
(No difference between CAF
intervention and genotype
distribution) *p=0.013
↑RPE (time) *p=0.020
↑RPE (PLA intervention)
*p=0.010
↑During steady state VO2 (CAF
intervention) *p=0.047
↑During steady state VO2 (time)
*p=0.007
↑RER (CAF intervention) *p=0.08
→RER (genotype distribution)
*p=0.709
↑VO2 (CAF intervention *p=0.757
↑CMJ height *p=0.001, SV
*p=0.022, BT9M *p=0.008 (CAF
intervention)
→Time to complete the MATT
*p=0.686, strength in the IHS test
*p=0.054, BT7M *p=0.065,
BT7M+GK *p=0.492, BT9M+GK
*p=0.093
↑BT7M (CAF intervention in AA
genotype) *p=0.013
→BT7M (C allele carriers)
*p=0.932
→ACC, DEC, BI frequency (CAF
intervention or genotype
distribution) *p=0.178, *p=0.051,
*p=0.556
↑Insomnia (C allele carriers)
*p=0.023

Effect Size

CMJ
AA genotype 0.28
AC/CC genotype 0.15
Sprint velocity test
AA genotype 0.84
AC/CC genotype 0.15
Modified agility t-test
AA genotype 0.03
AC/CC genotype − 0.05
Isometric handgrip
strength
AA genotype 0.00
AC/CC genotype 0.23
Ball throw from 7-m
AA genotype 0.34
AC/CC genotype − 0.02
Ball throw from 7-m with
a goalkeeper
AA genotype 0.39
AC/CC genotype − 0.23
Ball throw from 9-m
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Author
(year,
location)

Study
Design

Study Sample

Age
(year)

VO2max

Intervention

Control

Genotype
Distribution

Caffeine
Intake
(mg/day)

Pataky et al.
(2016), U.S.
[31]

RCT

Recreationally
trained men
(N=38)

21 ± 1

AA (n=21): 51
± 7, C (n=17):
51 ± 6
*ml/kg/min

6 mg/kg BW
CAF

Placebo (flavor +
saccharine)

AA (n=21), C
(n=17)

NA

Potgieter
(2013),
South Africa
[32]

RCT

Triathles
(N=26)

37.8 ±
10.6

NA

6 mg/kg BW

Placebo
(Canderel®)

AA (n=16),
AC (n=5), CC
(n=5)

NA

Outcomes

↑Power output (Ingestion+Rinse
CAF intervention) *p=0.01
↑Power output (Ingestion CAF
intervention) *p=0.12
↑Likely differences (Ingestion
CAF intervention to AC genotype)
*p=0.12
↑Power output (Ingestion+Rinse
CAF intervention in early subjects)
*p=0.0001
↑Power output (Ingestion CAF
intervention in early subjects)
*p=0.06
↑Power output (Rinse CAF
intervention in early subjects)
*p=0.16
↓Power output (Rinse CAF
intervention in late subjects)
*p=0.43
↓Swimming time (CAF
intervention) *p=0.05
↓Completion of the triathlon
time *p=0.02
↓RPE (CAF intervention) *p=0.87

Effect Size
AA genotype 0.40
AC/CC genotype 0.22
Ball throw from 9-m with
a goalkeeper
AA genotype 0.47
AC/CC genotype 0.05
ACC (number/min)
AA genotype 0.089
C genotype 0.52
DEC (number/min)
AA genotype 0.57
C genotype 0.0061
BI (number/min)
AA genotype 0.079
C genotype 0.31
AA/C genotype:
VO2max mL/kg/min 0.0

Data not presented
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Author
(year,
location)

Puente et
al. (2018),
Spain [33]

Study
Design

RCT

Study Sample

Elite
basketball
players
(N=19)

Age
(year)

NA

VO2max

NA

Intervention

3 mg/kg BW
CAF

Control

Placebo
(cellulose)

Genotype
Distribution

AA (n=10), C
(n=9)

Caffeine
Intake
(mg/day)

NA

Outcomes
↑Blood lactate levels (CAF
intervention) *p=0.04
Shakiness *p = 0.00, heart
palpitations *p = 0.01 and GIS
disturbances *p=0.01 (CAF
intervention)
↑Ablakov jump (AA genotype)
*p=0.03
→Sprint time in the CODAT test
with the ball (AA genotype)
*p=0.15
→Sprint time in the CODAT test
with the ball (C allele carriers)
*p=0.49
→Sprint time in the CODAT test
without the ball (AA genotype)
*p=0.36
→Sprint time in the CODAT test
without the ball (C allele carriers)
*p=0.37
→HR in basketball game
(Genotype distribution) * p >0.05
↑Perceived muscle power (CAF
intervention in AA genotype)
*p=0.04
↑Self-perceived endurance
capacity (CAF intervention in AA
genotype) *p=0.06
→Self-perceived endurance
capacity (C allele carriers) *p=0.50
→Ratings of perceived fatigue (AA
genotype or C allele carriers)
*p=0.20, *p=0.50
↑Insomnia (AA genotype)
→Side effects (Genotype
distribution) *p>0.05
↑BI (CAFF intake) *p<0.05
↑Mean jump height (CAF
intervention in AA genotype)
*p<0.05

Effect Size

Abalakov jump
AA genotype 0.15
AC/CC genotype 0.14
“Change-of-Direction
and Acceleration Test”
without the ball
AA genotype 0.12
AC/CC genotype − 0.06
“Change-of-Direction
and AccelerationTest”
with the ball
AA genotype 0.44
AC/CC genotype 0.0
Mean HR
AA genotype 0.21
C genotype 0.179
Peak HR
AA genotype 0.080
C genotype 0.46
BI (number/min)
AA genotype 0.38
C genotype 0.39
Perceived muscle power
(A.U.)
AA genotype 0.89
C genotype 0.65
Perceived endurance
(A.U.)
AA genotype 0.71
C genotype 0.0
Perceived exertion (A.U.)
AA genotype 0.45
C genotype 0.0
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Author
(year,
location)
Rahimi
(2018), Iran
[3]

Salinero et
al. (2017),
Spain [2]

Study
Design

Study Sample

Age
(year)

RCT

Resistancetrained men
(N=30)

NA

NA

6 mg kg BW
CAF

Placebo
(maltodextrin)

AA (n=14), C
allele carriers
(n=16)

RCT

Healthy active
participants
(N=21)

28.9 ±
7.3

NA

3 mg/kg BW
CAF

Placebo (??)

AA (n=5), C
allele carriers
(n=16)

VO2max

Intervention

Control

Genotype
Distribution

Caffeine
Intake
(mg/day)
NA

NA

Outcomes
↑BP repetitions at S1, S2, S3 (AA
genotype) *p=0.015 *p=0.0001
*p=0.001
↑BP repetitions at S1, S2 (CAF
intervention vs PLA intervention
in AA genotype) *p=0.003
*p=0.001
↑LP repetitions at S2, S3 (AA
genotype) *p=0.001 *p=0.024
↑LP repetitions at S2, S3 (CAF
intervention vs PLA intervention
in AA genotype) *p=0.012
*p=0.016
↑SR repetitions at S1, S2, S3 (CAF
intervention in AA genotype)
*p=0.005 *p=0.001 *p=0.007
↑SR repetitions at S1, S2, S3 (CAF
intervention vs PLA intervention)
*p=0.012 *p=0.027 *p=0.001
↑SP repetitions at S2, S3 (CAF
intervention vs PLA intervention
in AA genotype) *p=0.0001,
*p=0.012
↑Total repetitions for BP
*p=0.006, LP *p=0.03, SR *p=0.16
(CAF intervention in AA genotype
vs C allele carriers)
↑Total repetitions for BP
*p=0.004, LP *p=0.01, SR
*p=0.001, SP *p=0.048 (CAF
intervention vs PLA intervention
in AA genotype)
Total repetitions x genotype
distribution x CAF *p=0.002
→Reaction time (CAF or PLA
intervention) *p=0.31
→Reaction time (Genotype
distribution) *p=0.681

Effect Size
Data not presented

Peak power
AA genotype 0.04
AC/CC genotype 0.15
Mean power
AA genotype 0.07
AC/CC genotype 0.10
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Author
(year,
location)

Southward
(2016), New
Zealand
[35]

Study
Design

RCT

Study Sample

Recreationally
trained
athletes
(N=14)

Age
(year)

26.9 ±
7.93

VO2max

NA

Intervention

6 mg/kg BW
CAF

Control

Placebo
(maltodextrin)

Genotype
Distribution

AC (n=14)

Caffeine
Intake
(mg/day)

NA

Outcomes
↑Mean power output and peak
power in Wingate test (CAF
intervention) *p<0.001, *p=0.01
↑Mean power output and peak
power (CAF intervention) *p<0.05
↑Mean and peak power (CAF
intervention vs PLA intervention
in C allele carriers) *p<0.05
→Mean power, peak power
(Genotype distribution)
*p>0.05
→Fatigue index (CAF intervention)
*p=0.57
→Perceived muscle power,
perceived exertion (CAF
intervention)
→Perceived muscle power,
perceived exertion (Genotype
distribution) *p>0.05
→Side effect (CAF intervention)
*p>0.05
→Side effect (Genotype
distribution) *p>0.05
↑Nervousness (C allele carriers)
→5 or 10-km TT (CAF
intervention) *p=0.589, p=0.187
↑During the exercise HR (CAF
intervention) *p=0.062
→Intervention x HR x time
*p=0.257
→Resting HR (CAF intervention)
*p=0.25
→Concentric knee extensor
torque (CAF intervention) *p<0.05
→Intervention x time x concentric
knee extensor torque *p=0.808
↑Eccentric knee extensor torque
(CAF intervention) *p<0.05
→Eccentric knee extensor torque
x time x intervention *p=0.195

Effect Size
Perceived power
AA genotype 0.5
C genotype 0.5
Perceived exertion
AA genotype 0.0
C genotype 0.0
Fatigue Index
AA genotype 0.01
C carriers 0.15

10-km running time trial
AC genotype 0.34
HR
AC genotype 0.44
Concentric knee
extensor torque
AC genotype 0.25
Eccentric knee extensor
torque
AC genotype 0.44
SJ height
AC genotype 0.33
CMJ height
AC genotype 0.17
RPE
AC genotype 0.12
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Author
(year,
location)

Spineli et al.
(2020),
Brazil [36]

Study
Design

RCT

Study Sample

Competitive
adolescents
(N=100)

Age
(year)

15 ± 2

VO2max

AA (n=49):
44.3 ± 2.7 AC
(n=42):43.2 ±
2.4 CC (n=9):
45.8 ± 3.5
*ml/kg/min

Intervention

6 mg/kg BW
CAF

Control

Placebo
(cellulose)

Genotype
Distribution

AA (n=49) AC
(n=42) CC
(n=9)

Caffeine
Intake
(mg/day)

AA (n=49):
42.3 ± 39.8
AC (n=42):
58.6 ± 44.9,
CC (n=9): 32.8
± 23.9

Outcomes
↑Eccentric knee extensor torque
(CAF intervention vs PLA
intervention) *p=0.015
↑Knee extensor torque x time
(CAF intervention) *p=0.081
↑SJ height (CAF intervention)
*p=0.017
→Intervention x time x SJ height
*p=0.129
→CMJ height (CAF intervention)
*p=0.325
→Intervention x time x CMJ
height *p=0.209
→RPE (CAF intervention)
*p=0.309
→Intervention x time x RPE
*p=0.156
→Vigor (CAF intervention)
*p=0.197
↓Digit vigilance reaction times
(CAF intervention) *p<0.05
↓Rapid visual information
processing (CAF intervention)
*p<0.1
↑Vigor (CAF intervention)
*p=0.032
→Sleep quality *p=0.358, ease of
awakening *p=0.790, behavior
following sleep *p=0.457 (CAF
intervention)
→CMJ (CAF intervention x
genotype distribution or genotype
distribution) *p=0.935, *p=0.753
→SJ test (CAF intervention x
genotype distribution or genotype
distribution) *p=0.571, *p=0.832
→Agility time (CAF intervention)
*p=0.736

Effect Size

AA/AC genotype:
VO2max (ml/kg/min)
0.43
CAFF intake 0.38
AA/CC henotype
VO2max (ml/kg/min)
0.50
CAFF intake 0.30
Handgrip strength test
(kgf)
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Author
(year,
location)

Thomas et
al. (2020),
Canada [38]

Study
Design

RCT

Study Sample

Healthy
untrained
adults (N=20)

Age
(year)

25.5 ±
3.5

VO2max

AA (n=11):
32.3 ± 5.4 C
allele carriers
(n=9): 32.1 ±

Intervention

3x100mg/piece
gum

Control

Placebo (gum)

Genotype
Distribution

A (n=11) C
allele carriers
(n=9)

Caffeine
Intake
(mg/day)

NA

Outcomes
↓Agility (AC vs AA or CC
genotype) *AA p=0.037, *CC
p=0.018
→Agility (CAF intervention x
genotype distribution) *p=0.417
↑Sit-up and push-up tests (CAF
intervention) *p=0.001, p=0.004
→Sit-up and push-up tests
(Genotype distribution) *p=0.122
↑Total distance in Yo-Yo IR1 (CAF
intervention) *p=0.019
↓Yo-Yo IR1 (AC genotype)
*p=0.068
→RPE (CAF intervention x
genotype distribution or
genotype) *p=0.466, *p=0.502
→Handgrip test (CAF intervention
x genotype distribution or
genotype distribution) *p=0.210,
*p=0.096

C allele group, a main effect of
time was detected for HR and all
HRV indices during the PLA trial
*p<0.05

Effect Size
AA genotype 0.26
AC genotype 0.065
CC genotype 0.062
CMJ
AA genotype 0.11
AC genotype 0.13
CC genotype 0.04
Spike jump
AA genotype 0.14
AC genotype 0.05
CC genotype 0.01
Agility test
AA genotype 0.10
AC genotype 0.07
CC genotype − 0.37
Isometric handgrip
strength
AA genotype 0.17
AC genotype 0.07
CC genotype 0.06
Push-up
AA genotype 0.09
AC genotype 0.24
CC genotype 0.36
Sit-up
AA genotype 0.24
AC genotype 0.32
CC genotype 0.28
Yo–Yo IR1
AA genotype 0.31
AC genotype 0.36
CC genotype 0.12
RPE
AA genotype 0.22
AC genotype 0.37
CC genotype 0.16
AA/C genotype:
VO2max (ml/kg/min)
0.030
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Author
(year,
location)
Womack et
al. (2012),
U.S. [14]

Study
Design

RCT

Study Sample

Recreationally
competitive
cyclists
(N=35)

Age
(year)

25.0 ±
7.3

VO2max
7.8
*ml/kg/min
VO2max
(L/min) AA
(n=16): 4.30 ±
0.45 C allele
carriers
(n=19): 4.31 ±
0.58 /
VO2max
(ml/kg/min)
AA (n=16):
59.04 ± 9.29 C
allele carriers
(n=19): 59.61
± 10.31

Intervention

6 mg/kg BW
CAF

Control

Placebo (flour)

Genotype
Distribution

AA (n=16) C
allele carriers
(n=19)

Caffeine
Intake
(mg/day)
AA (n=16):
85.71 ±
106.49 C
(n=19): 86.62
± 145.40

Outcomes
↓Time diffrence was detected for
HR (CAFF trial) *p <0.05
↓40-km times (CAF intervention
vs PLA intervention and
intervention x genotype
distribution) *p<0.001, *0.005
↓40-km times (CAF intervention
in AA genotype vs C allele carriers)
*p<0.001, *p=0.04
↑VO2, HR (CAF intervention)
*p<0.001
↑VO2 (C allele carriers) *p=0.03
→RPE, RER (CAF intervention or
genotype distribution) p=NS

Effect Size

AA/C genotype:
CAFF intake 0.0071
AA/C genotype:
VO2max (L/min) 0.019
AA/C genotype:
VO2max (ml/kg/min)
0.058
RPE
AA genotype 0.062
C genotype 0.071
VO2(L/min)
AA genotype 0.44
C genotype 0.42
RER
AA genotype 0.22
C genotype 0.0
HR
AA genotype 0.86
C genotype 0.52

Abbreviations: 1RM: 1-repetition maximum; ACC: acceleration; A.U.; arbitrary units; BF: breathing frequency; BGI = blood glucose concentration; BI: body impacts; BLa: blood lactate concentration; BP: bench press; BT7M: ball
throw 7-m; BT7M+GK: ball throw 7-m with goalkeeper; BT9M: ball throw 9-m; BT9 + GK: ball throw 9-m with goalkeeper; BW: body weight; CAF: caffeine; CODAT: change-of-direction and acceleration test; CMJ: countermovement
jump; DBP: diastolic blood pressure; DEC: decelerations; GIS: gastrointestinal system; GK: goalkeeper; HR: heart rate; IHS: isometric handgrip strength; LP: leg press; MATT: modified agility t-test; MVIC: maximal voluntary
isometric contraction; MVT: maximal voluntary torque; MUAP: motor unit action potential amplitude; NA: Not applicable; NS: No significant; PLA: placebo; PVT: psychomotor vigilance test; PX: paraxanthine; RER: respiratory
exchange ratio; RPE: rating of perceived exertion; RT: recruitment threshold; SBP: systolic blood pressure; SP: shoulder press; SR; seated row; SV: sprint velocity test; HRV: post-exercise heart rate variability; TM: treadmill exercise;
TST: tennis skill test; TT: time-trial; VLEI: vastus lateralis echo intensity; VO2: rate of oxygen uptake; V̇E: minute ventilation; vs: versus.
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Sport Performance
ADORA2A: Four studies reported performance changes after ingesting caffeine. The
study samples ranged from 12–66 [10, 11, 12, 13]. Ergogenic effects on performance were
seen after caffeine ingestion. No significant results were seen in genotype distribution after ingesting 3 mg/kg caffeine in countermovement jump (CMJ), sprint velocity test (SV),
modified agility t-test (MATT), isometric handgrip strength (IHS), ball throw 7-m (BT7M),
ball throw 7-m with goalkeeper (BT7M+GK), ball throw 9-m (BT9M), ball throw 9-m with
goalkeeper (BT9M+GK) tests [12]. %VO2max peak and VO2max increased in C carriers
after consuming 5 mg/kg caffeine, and total work done in the caffeine group increased,
and in the TT genotype, %VO2max decreased. Total work done by C carriers was greater
than by the TT genotype [10]. Also, Glaister et al. reported significant changes in power
output after 5 mg/kg of caffeine [13]. Importantly, in a study that Grgic et al. conducted
on resistance-trained men, 3 mg/kg caffeine intake increased the muscular endurance,
CMJ and Wingate tests measure in C allele carriers [11]. The ESs of the TT genotype in
performance was 0.0038–0.75, while in C carriers they were 0.018–0.96 (see Table 1).
CYP1A2: In their systematic review, Grgic et al. [16] reported sixteen studies [2–4, 9,
12, 14, 22, 23, 27–29, 31–33, 35, 36] regarding the effect of acute caffeine consumption on
performance in the CYP1A2 gene that we also included in our systematic review. For this
reason, the same results were not included as we wanted our study to be a complementary
study. Four more studies were added [13, 24–26].
A total of 20 studies investigated performance changes after caffeine consumption.
Different performance tests were implemented in studies, such as measuring VO2max,
time trial tests, muscle power tests, isometric handgrip tests, bench press, leg press, shoulder press, seated row, countermovement jump, abalakov jump, spike jump and squat
jump, sprint velocity test, Wingate test, agility tests, different skill tests changing, reaction
time, response speed, number of lapses. In six studies, no effect of the genotype distribution was seen, while acute caffeine intake was affected [4, 13, 27, 29, 33, 36]. In three studies, no difference was detected with both the genotype and caffeine intake [23, 25, 26].
Nine studies found significant results in the genotype distribution [2, 3, 4, 9, 12, 14, 24, 33,
36]. Carswell et al. detected that 3 mg/kg caffeine intake decreased the reaction time, the
number of lapses and increased the slowest speed time in AA genotypes [4]. Guest found
improvements in cycling performance in the AA genotype after ingesting 2mg/kg or
4mg/kg caffeine [9]. Respectively, performance improvements in ball throwing and abalakov jump were seen in the AA genotype after 3mg/kg caffeine [12, 33]. Also, Womack et
al. reported improvements in cycling time after 6mg/kg caffeine on AA genotypes, and
Rahimi reported increases in bench press, leg press, seated row, shoulder press repetitions
in AA genotype [3, 14]. On the other hand, in C alleles, muscle power increased after ingesting 6 mg/kg [24]. Also an increase in mean and peak power after 3 mg/kg of caffeine
intake was seen [2]. Spineli et al. reported that a decrease in the agility test in the AC
genotype compared to the AA and CC genotypes [36]. Moreover, in four studies, VO2max
was measured after caffeine intake [13, 14, 25, 29]. Two of them reported no significant
effects [13, 25]. McGrath reported an increase in VO2max after 5 mg/kg caffeine, and Womack et al. reported an increase in VO2max in C allele carriers after 6 mg/kg of caffeine [14,
29]. The range of ESs in 10 studies for the AA genotype in performance was 0.049–3.39; in
9 studies for C carriers these were 0.0–1.27; in one study for the AC genotype it was 0.065–
0.37, and in two studies for the CC genotype it was 0.062–3.75 (see Table 2).
Quality Appraisal
The average score obtained from the PEDro checklist was calculated as 8.64 points
(range 7–9 points). 18 studies were classified as "excellent" in their methodological quality
and 7 as of "good" methodological quality. Individual scores are shown in Table 3.
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Table 3. Quality appraisal of the included studies by the PEDro scale [21, 37].
References

Item 1

Item 2

Item 3

Item 4

Item 5

Item 6

Item 7

Item 8

Item 9

Item
11
Yes

Score

Yes

Item
10
Yes

Algrain et al.
[23]
Carswell et al.
[4]
Colquhoun [24]

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

Figueiredo et
al. [26]
Fitzgerald [25]

Yes

Yes

Yes

Yes

Unclear
Yes

Yes

Yes

Yes

Yes

Giersch et al.
[27]
Glaister et al.
[13]
Grgic et al. [11]

No

Yes

Yes

No

Yes

Yes

Yes

Grgic et al. [22]

Yes

Yes

Guest [9]

Yes

Yes

Klein et al. [28]

Yes

Loy et al. [10]

Yes

Unclear
Yes

McGrath et al.
[29]
Munoz et al.
[12]
O’Connor et al.
[30]
Pataky et al.
[31]
Potgieter [32]

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Puente et al.
[33]
Rahimi [3]

Yes

Yes

Yes

Yes

Renda et al.
[34]
Salinero et al.
[2]
Southward [35]

Yes

Yes

Yes

Yes

Yes

Yes

Spineli et al.
[36]
Thomas et al.
[38]
Womack et al.
[14]

Yes

Yes

Yes

Yes

Yes

Yes

Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear
Unclear

Yes

Yes

Unclear
Yes

Yes

Yes

Yes

Yes

9

Yes

No

Yes

Yes

Yes

7

Yes

Yes

Yes

Yes

Yes

9

No

Yes

Yes

Yes

Yes

Yes

8

Yes

Yes

Yes

Yes

Yes

Yes

Yes

9

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

9

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

9

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

9

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

9

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

8

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

9

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

9

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

9

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

8

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

9

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

8

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

9

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

9

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

9

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

9

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

9

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

9

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

9

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

9

8
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4. Discussion
This systematic review finds that different doses of acute caffeine intake can affect
the physiological state and performance of individuals with genotype distributions of the
CYP1A2 and ADORA2A gene. Studies acknowledged that there is no single gene that affects caffeine metabolism in the body [4, 10–13, 30, 34], but strategies are insufficient to
definitely prove which gene is more efficient and also which genotype benefits more with
caffeine’s ergogenic use. In studies with the same study groups of in CYP1A2 and
ADORA2A gene polymorphisms [4, 12, 13], Carswell et al. did not find any difference in
the ADORA2A gene, while in the CYP1A2 gene, the AA genotype has significant improvements in performance following the 3mg/kg caffeine [4]. Also, Glaister et al. did not report
any changes in the ADORA2A gene, but improvement in RER was observed in the
CYP1A2 gene [13]. On the other hand, according to the ADORA2A gene polymorphism,
urine production and activeness increased in the TT genotype, while no differences were
seen for the CYP1A2 genotype distributions. Moreover, performance improvements were
observed in 7-m ball throw in the AA genotypes of CYP1A2 gene, and insomnia rates
increased in C carriers, but no significant effects of the ADORA2A gene distributions were
observed [12]. In one study with only C carriers of the ADORA2A gene, all performance
tests (maximum repetitions at 85%, 1-repetition maximum (1RM), mean power matched
for repetitions, mean velocity matched for repetitions, peak power matched for repetitions, peak velocity matched for repetitions, vertical jump height in the CMJ test, peak
power in the Wingate test, mean power in the Wingate test, minimum power in the Wingate test) showed significant increases after 3mg/kg of caffeine intake [11]. With the same
performance test in the CYP1A2 gene distributions, only an increase in the mean velocity
in C allele carriers was found; also increased vigor/activeness was observed [22]. A comparison of these two studies explains the importance of the ADORA2A gene in the ergogenic use of caffeine; therefore, more studies are needed with bigger study samples and
in all genotypes for the ADORA2A gene polymorphisms.
Apart from gene variations, ergogenic responses to caffeine can change according to
the amount, type of replacement, gender and age [4, 39–42]. Caffeine is classified as "generally considered safe" by the U.S. Food and Drug Administration (FDA) [43]. Caffeine
can be unsafe for individuals with certain genetic polymorphisms or certain medical conditions (e.g., hypertension, heart conditions, gastrointestinal problems, diabetes), and it is
difficult to predict its effects at higher doses [44]. In most people, caffeine contributes to a
cognitive response that includes increased activeness and attention [45–47] and has roles
mainly in an increase in blood pressure (BP) [48]. In the ADORA2A polymorphism, increased activeness and urine production were seen in the TT genotype after ingesting 3
mg/kg of caffeine before the exercise [12]. On the other hand, in the CYP1A2 polymorphism, after 6 mg/kg of caffeine intake, shakiness, heart palpitations and gastrointestinal
system (GIS) disturbances were seen [32]. Moreover, insomnia was seen in both the AA
genotypes and C carriers after consuming 3 mg/kg [12, 33].
HR plays an important role in athletes’ performance and training. Stork et al. [49]
found that HR is always associated with physiological limits, and therefore the heart rate
is suitable for measuring the performance of athletes. In the ADORA2A gene, HR increased more in C carriers after ingestion of 5 mg/kg of caffeine [10]. The peak change SBP
increased in the TT genotype following 3 mg/kg of caffeine [34]. In the CYP1A2 gene, exercise HR increased in the AA genotype after ingesting 6 mg/kg of caffeine [25,28]. Guest
reported HR increases in the AC genotypes after 4 mg/kg of caffeine intake, while and a
decrease was seen in the CC genotype [9]. Meanwhile, a decrease in time for HR was detected in C carriers so the recovery time was improved after 3x100mg/piece of gum caffeine [38]. The quick HR decrease, or decreased HR in exercise, is a wanted thing to compare the performance for an athlete. In a study, the top 5 athletes in a competition had
higher HRs in exercise than other athletes [50]. Therefore, the decrease in HR in C carriers
can be evidence of a probable performance increase. However, in all cases, HR data can
only be measured in a limited number of aspects for performance or training response
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and, therefore, need to be combined with additional parameters [51]. RPE is an indicator
of how difficult the work is done, and in the study, 4mg/kg of caffeine intake decreased
RPE in the CYP1A2 gene AA genotype. Moreover, Puente et al. suggested the same about
3 mg/kg of caffeine intake [9, 33]. On the other hand, Fitzgerald reported that C allele
carriers had a decrease in RPE after 6 mg/kg of caffeine intake [25]. Also, in the ADORA2A
gene, pain ratings decreased in the TT genotype and increased in the CC genotype; RPE
and arm swelling decreased in the CC genotype, while caffeine sensitivity increased after
the exercise with 5 mg/kg of caffeine [30]. Therefore, caffeine can be a potential ergogenic
for athletes. Furthermore, in the use of caffeine for ergogenic effects, tolerance may develop [52]. It has been shown that the suppressive effect of acute caffeine intake disappears
after 3 to 5 days of repeated caffeine consumption [53]. In addition, studies indicated that
a tolerance in HR and BP can occur after chronic caffeine intake, and Beaumont et al.
demonstrated that regular daily consumption of 3 mg/kg of caffeine can reduce the response to ergogenic effects of acute 3 mg/kg of caffeine consumption before the exercise
[54–56]. This indicates that genetic factors may be involved in developing incomplete tolerance. therefore, it is important to determine the proper dose, frequency and effects of
the polymorphisms on the athletes for maximum performance and side effects.
Limitations
The significant limitations are small sample sizes in each study; most measured parameter were different and not suitable to processes of a quantitative appraisal. Most studies measured the effect of caffeine intake without applying any wash-out, which may affect the results obtained in the studies. By this, the probable tolerance that may occur and
can affect the results of the trials. Fasting state of satiety or a different ergogenic supplement use is unknown. There are different doses of caffeine intake in studies, and there is
no standardization in this regard. Different exercise types, durations and contributor
groups (resistance trainer, strength sports, team sports, etc.) were used, so exercise type
and the variations on the performance cannot be interpreted.
5. Conclusions
Even studies for caffeine metabolism are usually interpreted with the CYP1A2 gene.
This study provides the importance of the ADORA2A gene polymorphism. As explained,
C alleles usually show performance improvements after caffeine intake. In the CYP1A2
polymorphism, different performance changes were observed, and controversial results
were inconsistent. On the other hand, many physiological and ergogenic effects can occur
due to caffeine, but no consistent reports are presented for genotypes either. This study
indicates the differences between the two genes, but the studies on genotypes are mostly
inconsistent and unpredictable. It is important to determine the proper dose, frequency
and effects of the polymorphisms on the athletes, for maximum performance, predict side
effects and, more importantly, to specify a personalized ergogenic guideline. Consequently, significant results in genotype distributions in studies are detected; however,
there are controversial results about which genotype may be affected more, so there is a
need for efficient studies with a increased number of study samples.
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